Market Size of Infertility Drugs Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 6.50 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Infertility Drugs Market Analysis
The infertility drugs market is expected to register a CAGR of 6.5% over the forecast period.
The outbreak of COVID-19 adversely impacted the market. The disruption in the supply chain during COVID-19 and the delay in the delivery of essential products required for the manufacturing of infertility drugs adversely affected the infertility drugs market. Also, suspending fertility centers to avoid coronavirus transmission among the population impacted the market growth. For instance, according to an article published in the National Library of Medicine in April 2021, it was observed that reproductive therapy was suspended during the pandemic's initial phase, creating anxiety and psychological suffering among women undergoing fertility treatment. Additionally, according to an article published in the Annals of Medicine and Surgery in June 2022, it was found that in-vitro fertilization cycles were discontinued due to patients testing positive for COVID-19 in Indonesia. Thus, such suspended procedures impacted the demand for infertility drugs during the pandemic. However, with the released restrictions and resumed fertility treatment services and centers, the studied market witnessed significant growth in the demand for infertility drugs owing to the increased number of people's visits to fertilization centers.
Factors such as the increasing global prevalence of stress and lifestyle-related disorders among men and women, the rise in healthcare awareness, and the increasingly aging female population are expected to boost the market growth.
Infertility continues to pose a global health challenge owing to demographic shifts and continuous lifestyle problems, including obesity, anxiety, stress, and other factors that cause delayed childbearing. For instance, according to the data published by Alcoholic Beverage Consumption Statistics published in February 2023, about 63% of adults in the United States who were 18 or older drank alcohol during 2021-2022. Additionally, as per the data published in Alcohol Consumption Statistics United Kingdom in February 2023, it was observed that 12.5% of adults in the United Kingdom reported being teetotal, compared to the country's adult alcohol consumption rate of 71.2% who drink at least once a week. Thus, the high consumption of alcohol affects fertility in both males and females. It, in turn, is anticipated to fuel the demand for infertility drugs over the forecast period.
The prevalence of poor fertility among the population is also the key factor driving the market growth. For instance, according to an article published by the National Library of Medicine, in July 2022, about 15% of American couples and at least 180 million other people worldwide suffer from infertility. Also, it is estimated that 9% of Australian men and 8% to 12% of Eastern European men experience infertility issues. Thus, the high prevalence of infertility among men population across the globe is expected to increase the demand for effective drugs, thereby propelling market growth.
Furthermore, the increasing government and organization focus on launching various campaigns to raise awareness regarding fertility care and treatment and the factors that cause infertility problems among the population. For instance, in July 2022, Oasis Fertility launched the Infertility Knows No Gender campaign to commemorate World IVF Day. IVF offers a ray of hope to millions of couples struggling with infertility. Also, in April 2022, Walgreens launched a fertility awareness campaign in support of National Infertility Awareness Week. Such initiatives are anticipated to raise the demand for IVF treatment, which is anticipated to fuel the market growth over the forecast period.
Therefore, the studied market is expected to grow over the forecast period due to the factors above, such as the high prevalence of poor fertility, increasing sedentary lifestyle, and a growing number of awareness campaigns. However, the stringent regulatory framework for drug approval will likely impede the growth of the infertility drugs market over the forecast period.
Infertility Drugs Industry Segmentation
As per the scope of the report, infertility is the inability of a woman to become pregnant after one year (or longer) of unprotected sex. The fertility rate decreases with age 35 or above in both men and women. Medicines that regulate or stimulate ovulation are known as fertility drugs. Fertility drugs are the main treatment for infertile women due to ovulation disorders. Fertility drugs generally work with natural hormones, such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), to trigger ovulation. The Infertility Drugs Market is segmented by drug class (gonadotrophins, aromatase inhibitors, Selective Estrogen Receptor Modulators (SERMs), biguanides, and other drug classes), end user (male and female), distribution channel (hospital pharmacies, retail pharmacies, and other distribution channels), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
By Drug Class | |
Gonadotrophins | |
Aromatase Inhibitors | |
Selective Estrogen Receptor Modulators (SERMs) | |
Biguanides | |
Other Drug Classes |
By End User | |
Male | |
Female |
By Distribution Channel | |
Hospital Pharmacies | |
Retail Pharmacies | |
Other Distribution Channels |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Infertility Drugs Market Size Summary
The infertility drugs market is poised for growth, driven by a combination of factors including the increasing prevalence of infertility, lifestyle-related disorders, and an aging population. The market experienced setbacks during the COVID-19 pandemic due to supply chain disruptions and the temporary suspension of fertility treatments, which led to a decline in demand. However, as restrictions eased and fertility services resumed, the market saw a resurgence in demand. The rising awareness of healthcare and the impact of lifestyle choices, such as alcohol consumption, on fertility are expected to further propel market growth. Government and organizational initiatives aimed at raising awareness about fertility issues and treatments are also contributing to the market's expansion.
The gonadotrophin segment is anticipated to witness significant growth due to its high efficacy in treating infertility and the introduction of new products. The increasing number of research studies and clinical trials supporting the effectiveness of gonadotropin drugs is expected to boost their adoption. North America is projected to hold a substantial market share, driven by the rising incidence of infertility and related health issues, as well as increased demand for advanced infertility treatments. The market is moderately competitive, with key players like Ferring Pharmaceuticals, Pfizer, and Merck KGaA actively participating. Recent developments, such as the production of recombinant hormones in Russia and FDA approvals for new drugs, indicate ongoing innovation and expansion within the market.
Infertility Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Global Prevalence of Stress and Life-style Disorders among Men and Women
-
1.2.2 Rise in Healthcare Awareness along with Increasing Aging Female Population
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulatory Framework that Delays the Approval of Products
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Drug Class
-
2.1.1 Gonadotrophins
-
2.1.2 Aromatase Inhibitors
-
2.1.3 Selective Estrogen Receptor Modulators (SERMs)
-
2.1.4 Biguanides
-
2.1.5 Other Drug Classes
-
-
2.2 By End User
-
2.2.1 Male
-
2.2.2 Female
-
-
2.3 By Distribution Channel
-
2.3.1 Hospital Pharmacies
-
2.3.2 Retail Pharmacies
-
2.3.3 Other Distribution Channels
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Infertility Drugs Market Size FAQs
What is the current Global Infertility Drugs Market size?
The Global Infertility Drugs Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)
Who are the key players in Global Infertility Drugs Market?
Ferring Pharmaceuticals Inc, Pfizer Inc., Merck KGaA, Novartis International AG and Bayer AG are the major companies operating in the Global Infertility Drugs Market.